Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Walsh

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Leukemia & Lymphoma|February 18, 2011
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)C Tom Kouroukis, Louis A V Fernandez, Michael Crump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials groupScott A Laurie, Isabelle Gauthier, Andrew Arnold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Interleukin-21 has activity in patients with metastatic melanoma: a phase II studyTeresa M Petrella, Richard Tozer, Karl Belanger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163Susan L Ellard, Mark Clemons, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials groupGraham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Leukemia & Lymphoma|February 18, 2011
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)C Tom Kouroukis, Louis A V Fernandez, Michael Crump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials groupScott A Laurie, Isabelle Gauthier, Andrew Arnold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Interleukin-21 has activity in patients with metastatic melanoma: a phase II studyTeresa M Petrella, Richard Tozer, Karl Belanger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163Susan L Ellard, Mark Clemons, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials groupGraham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
Pageof 4